What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report

• Main Authors: Morgane Guillou-Landreat, Antoine Dany, Gaëlle Challet-Bouju, Edouard Laforgue, Juliette Leboucher, Jean Benoit Hardouin, Caroline Victorri-Vigneau, Marie Grall-Bronnec
• Format: Article
• Language: English
• Published: MDPI AG 2021-02-01
• Series: International Journal of Environmental Research and Public Health
• Subjects: opiate medication treatment; buprenorphine; methadone; daily clinical practice
• Online Access: https://www.mdpi.com/1660-4601/18/4/1425
• ISSN: 1661-7827; 1660-4601

(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment. Pharmacological therapy for OUD involves treatment with opioid agonists (OMT) tailored to individual profiles. The aim of our study in daily clinical practice was to compare the profiles of patients treated with methadone (MTD) and those using buprenorphine (BHD or BHD-naloxone-NX). (2) Methods: A cross-sectional multicentre study explored the psychological, somatic and social profiles of patients with Opioid Use Disorder (OUD) following Opioid Maintenance Treatment (BHD, BHD/NX, or MTD). Descriptive and comparative analyses were performed. (3) Results: 257 patients were included, a majority were men using heroin. A total of 68% (178) were on MTD, 32% (79) were on BHD. Patients with MTD were significantly more likely to report somatic damage, and more likely to be younger and not to report oral or sublingual use as the main route for heroin or non-medical opioids. (4) Conclusions: In daily clinical practice, somatic damage was significantly more severe among MTD patients. Age and route of administration also differed, and our results could raise the issue of the type of OMT prescribed in case of non-medical use of prescribed opioids. These hypothesis should be confirmed in larger studies.